Results 321 to 330 of about 384,579 (349)

Targeting the microbiota‐miRNA‐protease axis: A new therapeutic avenue in melanoma

The FEBS Journal, EarlyView.
Modulation of extracellular matrix (ECM) turnover is central to melanoma progression and metastasis, driven largely by ECM proteases. This review highlights the epigenetic regulation of ECM proteases by microRNAs and their roles in melanoma growth, invasion, and immune modulation.
Elias N. Katsoulieris, Paraskevi Ioannou, Nikolaos A. Afratis   +2 more
wiley   +1 more source

PTPN18 functions as a tumor suppressor in breast cancer by negatively regulating cyclin E. [PDF]

Int J Oncol
Zhang N, Wang T, Bai B, Zhang X, Xu W, Chen W, Yu Y, Wang B.   +7 more
europepmc   +1 more source

Frontiers in Cell-Cycle-Targeting Therapies: Addressing the Heterogeneity of the Cancer Cell Cycle. [PDF]

Cancers (Basel)
Ganesan IP, Kiyokawa H.
europepmc   +1 more source

Some of the next articles are maybe not open access.

Related searches:

Inhibitors of Cyclin-Dependent Kinase 1/2 for Anticancer Treatment.

Medicinal Chemistry, 2020
BACKGROUND The cell cycle is regulated by cyclin-dependent kinases (CDKs) and their cognate cyclins, along with their endogenous inhibitors (CDKIs). CDKs act as central regulators in this process.
J. Mou, Danghui Chen, Yanru Deng
semanticscholar   +3 more sources

OC-0427 Targeting Cyclin-Dependent Kinase 1 to Radiosensitize Pancreatic Cancer

Radiotherapy and Oncology, 2023
Adam R Wolfe, S. Van Matre, R. Eluvathingal, O. Zúñiga, H. Rodrigues, F. Xia   +5 more
semanticscholar   +2 more sources

3D-QSAR CoMFA study on oxindole derivatives as cyclin dependent kinase 1 (CDK1) and cyclin dependent kinase 2 (CDK2) inhibitors.

Medicinal Chemistry, 2007
Cyclin dependent kinases have emerged as important drug targets with a multitude of therapeutic potentials for their inhibitors. With the purpose of designing new chemical entities with enhanced inhibitory potencies against cyclin dependent kinase 2 (CDK2) and cyclin dependent kinase 1 (CDK1), the 3D-QSAR CoMFA
S. Singh, Nigus Dessalew, P. Bharatam
semanticscholar   +3 more sources

Quantitative structure-activity relationships of cyclin-dependent kinase 1 inhibitors

Biochemistry (Moscow) Supplement Series B: Biomedical Chemistry, 2007
A new approach for quantitative structure-activity relationships based on MNA descriptors, fuzzy gradation method and self-consistent regression has been proposed. This approach has been realized in the computer program GUSAR (General Unrestricted Structure Activity Relationships). Our method has been validated on CDK1 inhibitors.
A V, Zakharov, A A, Lagunin, D A, Filimonov, V V, Poroĭkov   +3 more
openaire   +2 more sources

Pharmacological Cyclin-Dependent Kinase Inhibitors as HIV-1 Antiviral Therapeutics

Current HIV Research, 2003
Human immunodeficiency virus type 1 (HIV-1) can infect quiescent cells; however, viral production is restricted to actively proliferating cells. Recent evidence has indicated that HIV-1 viral proteins, Vpr and Tat, perturb the cell cycle to optimize HIV-1 replication. Vpr arrests the cell cycle at G2 by inactivating the cyclin B/cdk1 complex.
Cynthia, de la Fuente, Anil, Maddukuri, Kylene, Kehn, Shanese Y, Baylor, Longwen, Deng, Anne, Pumfery, Fatah, Kashanchi   +6 more
openaire   +2 more sources

Cyclin Dependent Kinase 1 Inhibitors: A Review of Recent Progress

Current Medicinal Chemistry, 2011
Cyclin dependent kinases (CDKs) are a family of proteins involved in the regulation of cell cycle progression and attractive targets in oncology. The regulation of CDKs activities is achieved by their association with cyclin partners and kinases, phosphatases and specific inhibitors.
Q, Wang, L, Su, N, Liu, L, Zhang, W, Xu, H, Fang   +5 more
openaire   +2 more sources

Molecular models of cyclin-dependent kinase 1 complexed with inhibitors

Biochemical and Biophysical Research Communications, 2004
Roscovitine and flavopiridol have been shown to potently inhibit cyclin-dependent kinase 1 and 2 (CDK1 and 2). The structures of CDK2 complexed with roscovitine and deschoroflavopiridol have been reported, however no crystallographic structure is available for complexes of CDK1 with inhibitors.
Canduri, F., Uchoa, H. B., de Azevedo, W. F.   +2 more
openaire   +3 more sources